TipRanks
Go Ultimate55% OFF

Spok Holdings (FQV) AI Stock Analysis

1 Followers
DE:FQV

Spok Holdings

(Frankfurt:FQV)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring healthcare communications baseRecurring contracts across software, managed services and paging provide revenue visibility and reinforce customer retention. Long-standing hospital relationships and Spok’s leading U.S. paging position support an installed-base advantage while the company expands higher-value clinical communications offerings.
Negative Factors
Sharp revenue contractionA sharp decline in trailing revenue raises concern about the stability of Spok’s earnings base, even though margins remain strong. If lower revenue persists, fixed operating requirements and reduced scale could make it harder to sustain profitability and cash generation.

Spok Holdings (FQV) vs. iShares MSCI Germany ETF (EWG)

-25%-20%-15%-10%-5%0%5%10%15%DE:FQV+1.60%EWG+5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 250.64M
Dividend Yield
10.09%
Average Volume (3M)
242
Price to Earnings (P/E)
13.4
Beta (1Y)
0.31
Revenue Growth
-8.24%
EPS Growth
5.27%
Country
Germany
Employees
415
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Spok Holdings Business Overview & Revenue Model

Company Description

Spok Holdings, Inc., operating primarily through its subsidiary, Spok, Inc., specializes in providing advanced communication solutions tailored for the healthcare sector. These crucial services span a wide international footprint, covering the United...

Spok Holdings Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:17.21%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call balanced clear operational and financial progress (notably a 92% sequential bookings increase, record adjusted EBITDA, expense reductions, strong managed services growth, significant license revenue growth, and an $8M spectrum sale) against near‑term demand and booking dynamics (longer sales cycles, preference for shorter contract terms, slight revenue midpoint reduction, and modest wireless unit declines). Management retained the adjusted EBITDA midpoint and emphasized capital returns and continued investment in product development, signaling confidence in the company’s ability to offset revenue pressure with margin and cash generation initiatives. Overall, the tone was constructive with caution about near‑term revenue visibility.

Positive Updates

Large Sequential Increase in Software Bookings
Delivered a nearly 92% sequential increase in software operations bookings in Q2, driven by several large enterprise deals (including 14 six-figure and 1 seven-figure new customer contracts).

Negative Updates

Slight GAAP Net Income Decline and One-Time Costs
GAAP net income for Q2 was $4.1M ($0.20 per diluted share) vs $4.6M ($0.22) prior year; Q2 included $1.5M of severance and restructuring expense related to the strategic realignment.

Company Guidance

Management revised 2026 guidance to total revenue of $132.5M–$139.5M (midpoint $136M) and adjusted EBITDA of $28M–$32M (midpoint $30M), with wireless revenue now expected at $67M–$70M and software revenue $65.5M–$69.5M; the revenue midpoint was trimmed due to lumpiness in bookings and a pipeline where deals are taking longer and skewing to shorter/cancelable terms despite a 92% sequential jump in software operations bookings in Q2. Management said strategic realignment and cost reductions should offset revenue pressure, ARPU was stable at $8.20, Q2 license revenue was $3.6M (vs. $2.4M a year ago) and managed professional services totaled $2.3M (up 53% YoY), and they now expect to exit 2026 with $26M–$29M in cash (Q2 cash $16.6M) including a >$7M Q3 cash contribution from the $8M spectrum sale.

Spok Holdings Risk Analysis

Spok Holdings disclosed 25 risk factors in its most recent earnings report. Spok Holdings reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Spok Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:FQV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
OPRXOPRX70Outperform$177.25M38.303.60%―-5.82%―
CCLDCCLD62Neutral$73.09M24.6416.56%―15.07%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NRCNRC50Neutral$536.62M79.57103.40%2.66%3.37%-59.53%
HCATHCAT47Neutral$118.91M-0.39-129.70%―-7.54%-143.41%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:FQVOPRXCCLDNRCHCATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:FQV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:FQVSpok Holdings10.700.070.65%
OPRXOptimizerx Corporation9.33-9.83-51.30%
CCLDCarecloud, Inc.1.72-1.23-41.69%
NRCNational Research24.0710.4676.89%
HCATHealth Catalyst1.44-1.61-52.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.